# US 2009/0264405 A1 · Cetp Inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2009/0264405 A1
- Document ID: US20090264405A1
- Status: Published application
- Kind: A1
- Application number: 12/083,324
- Filed: 2006-10-30
- Published: 2009-10-22
- Earliest claimed: 2005-10-31
- Assignees: Merck Sharp & Dohme Corp.
- Inventors: Amjad Ali; Julianne A. Hunt; Florida Kallashi; Jennifer Kowalchick; Dooseop Kim; Cameron J. Smith; Peter J. Sinclair; Ramzi F. Sweis; Gayle E. Taylor; Christopher F. Thompson; Liya Chen; Nazia Quraishi
- Web page: https://patentgrep.com/patent/US20090264405A1

## CPC

- C07D 263/57: Aryl or substituted aryl radicals
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 235/18: with aryl radicals directly attached in position 2
- C07D 239/74: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
- C07D 277/64: with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
- C07D 277/66: with aromatic rings or ring systems directly attached in position 2
- C07D 413/04: directly linked by a ring-member-to-ring-member bond
- C07D 413/10: linked by a carbon chain containing aromatic rings
- C07D 413/12: linked by a chain containing hetero atoms as chain links
- C07D 413/14: containing three or more hetero rings
- C07D 471/04: Ortho-condensed systems
- C07D 471/10: Spiro-condensed systems
- C07D 487/04: Ortho-condensed systems
- C07D 495/10: Spiro-condensed systems
- C07D 498/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Compounds of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis.

## Claims

### Claim 1

A compound having Formula I, or a pharmaceutically acceptable salt thereof, wherein
Three of the groups W, X, Y and Z represent ═CH—, and the fourth of the groups W, X, Y, and Z represents ═CH—, ═N—, or ═N(—O)—, wherein the H of each ═CH— group optionally is replaced with a substituent group Ra, provided that at least one of the H groups is replaced with a substituent group Ra;
Q is selected from the group consisting of O, S, —CH═N—, and —N(R2)—, where the carbon of —CH═N— is attached to the 6-membered ring;
A is a difunctional cyclic group selected from 1,4-phenylene, 2,5-pyridinylene, 2,5-thienylene, 2,5-furylene, 2,5-pyrazinylene, 2,5-pyrimidinylene, and 1,4-bicyclo[2,2,2]octylene, wherein A is optionally substituted with 1-3 substituent groups Rb;
Each Ra substituent is independently selected from the group consisting of halogen, —OH, —CN, —NO2, —N(R9)2, C1-C7alkyl, OC1-C7alkyl, C2-C7alkenyl, C2-C7alkynyl, —C(═O)H, —C(═O)C1-C5alkyl, —N(R9)C(═O)C1-C5alkyl, pyridinyl, N-oxidopyridinyl, phenyl, —OPhenyl, piperidinyl, pyrimidinyl, C3-C6cycloalkyl, methyldioxolanyl, furyl, thienyl, oxazolyl, morpholinyl, isoxazolyl, —N(R9)C(═O)OC1-C5alkyl, —C(═NH)NH2, —C(═O)OC1-C5alkyl, —S(O)xC1-C7alkyl, —CH2S(O)xC1-C5alkyl, —OC(═O)C1-C5alkyl, and —OCH2C(═O)OCH2-phenyl; wherein C1-C7alkyl, C1-C5alkyl, C2-C7alkenyl, and C2-C7 alkynyl in each occurrence is optionally substituted with 1-7 halogens and is optionally substituted with one substituent selected from the group consisting of —OH, —CN, —SH, —S(O)xC1-C3alkyl, —N(R9)2, —OC1-C3alkyl, —OCF3, —OC(═O)CH3, phenyl, C3-C6cycloalkyl, —OC3-C6cycloalkyl, and —OCH2-Phenyl; wherein when Ra is phenyl or comprises a phenyl group, said phenyl group is optionally substituted with 1-3 substituents independently selected from halogen, C1-C3alkyl optionally substituted with 1-5 halogens, —OC1-C5alkyl optionally substituted with 1-5 halogens, —CN, and —C(═O)N(R9)2;
x is an integer from 0-2;
Each Rb is independently selected from the group consisting of halogen, C1-C3alkyl, C2-C3alkenyl, C2-C3alkynyl, —OCH3, and —OCF3, wherein each alkyl, alkenyl, and alkynyl substituent is optionally substituted with 1-3 halogens;
R2 is independently selected from H, C1-C5alkyl, C2-C5alkenyl, C2-C5alkynyl, —CH2C3-C6cycloalkyl, and —CH2-Phenyl, wherein each alkyl, alkenyl, and alkynyl substituent is optionally substituted with 1-7 halogens, and said phenyl and cycloalkyl groups are optionally substituted with 1-3 substituent groups independently selected from halogen, CH3, CF3, —OCH3, and —OCF3;
B is selected from the group consisting of:
—N(R9)(C(═O))DR3,
—N(R9)(C(═O))DR7,
—N(R9)(C(═O))R3,
—N(R9)(C(═O))R7,
—N(R9)(C(═O))OCH2R3,
—N(R9)D(C(═O))R7,
—N(R9)DR3,
—N(R9)D2R7,
—OD2R3,
—SD2R3,
—C(═O)CH2CH2R4,
-D2(C(═O))R7,
-D2R3,
-D2R7, and
—R3;
D is a difunctional group selected from C1-C7alkylene, C2-C5alkenylene, and C2-C5alkynylene, wherein said alkylene group optionally has one difunctional group O, S, —NH— or —N(C1-C3alkyl)- between two carbon atoms of D, and said alkylene, alkenylene, and alkynylene groups are optionally substituted with 1-9 substituents independently selected from 1-7 halogens and optionally 1-2-OH groups;
D2 is a difunctional group selected from C2-C7alkylene, C2-C5alkenylene, and C2-C5alkynylene, wherein said alkylene group optionally has one difunctional group O, S, —NH— or —N(C1-C3alkyl)- between two carbon atoms of the alkylene group other than carbonyl, and said alkylene, alkenylene, and alkynylene groups are optionally substituted with 1-9 substituents independently selected from (a) 1-7 halogens, (b) 1-2 substituents independently selected from —N(R9)2, —CN, —NO2, —OC1-C3 alkyl optionally substituted with 1-3 halogens, —C(═O)OH, —C(═O)H, —C(═O)OC1-C5alkyl optionally substituted with 1-7 halogens, —C(═O)C1-C5alkyl optionally substituted with 1-7 halogens, —C(═O)N(R9)2, (c) 1-2—OH groups, and (d) an oxo group on a carbon atom between two other carbon atoms of the alkylene group;
R3 is selected from the group consisting of R4, -T-R4, and —R5;
R7 is selected from the group consisting of —OC1-C7alkyl, —CH2S(O)2C1-C7alkyl, C5-C10alkyl, —NR9C1-C7alkyl, —NR9C(═O)OC1-C7alkyl, —OC(═O)OC1-C7alkyl and —OSi(R8)3, wherein the C5-C10alkyl and C1-C7alkyl groups of R7 are optionally substituted with 1-9 halogens and are optionally substituted with one group selected from —N(R9)2, —N(R9)C(═O)OC1-C7alkyl, —N(R9)C(═O)C1-C7alkyl, and —OH, wherein the C1-C7alkyl groups of the —N(R9)C(═O)OC1-C7alkyl and —N(R9)C(═O)C1-C7alkyl substituents on R7 are optionally substituted with 1-9 halogens;
T is selected from —O—, —N(R9)—, and —S—;
Each R8 group is independently selected from C1-C5alkyl, which is optionally substituted with 1-7 halogens;
R4 is a cyclic group selected from the group consisting of
(a) C3-C8Cycloalkyl which optionally comprises 1-2 double bonds;
(b) Bicyclic C6-C12Cycloalkyl optionally comprising 1-2 double bonds;
(c) A 4-8 membered saturated or partly unsaturated heterocyclic ring having 1-2 ring members independently selected from —O— and —N(R6)—, said heterocyclic ring being connected to the left hand part of Formula I through a carbon atom of the heterocyclic ring, wherein said heterocyclic ring is optionally fused to an aromatic ring selected from phenyl and naphthyl or to a C5-C7Cycloalkyl;
(d) An aromatic ring selected from phenyl and naphthyl; and
(e) A 5-7 membered heteroaromatic ring having 1-3 heteroatoms independently selected from N, S, and O, and optionally having one —C(═O)— group as a ring member, said heteroaromatic ring being connected to the left hand part of formula I through a carbon atom of the heteroaromatic ring, wherein said heteroromatic group is optionally fused to an aromatic ring selected from phenyl and naphthyl;
Wherein said cyclic groups R4 defined in (a)-(e), including optional fused rings, are optionally substituted with 1-7 substitutents independently selected from halogen, C1-C5alkyl, OC1-C5alkyl, phenyl, —NO2, —C(═O)C1-C5alkyl, —C(═O)OC1-C5alkyl, —C(═O)OH, and —NR9C(═O)C1-C5alkyl, wherein C1-C5alkyl and OC1-C5alkyl in all uses are optionally substituted with 1-9 halogens, and said phenyl is optionally substituted with 1-5 substituents independently selected from halogen, CH3, CF3, —OCH3, and —OCF3;
R5 is a saturated or partly unsaturated 5-8 membered monocyclic heterocyclic group or a saturated or partly unsaturated 6-10 membered bicyclic heterocyclic group, wherein said heterocyclic group has a heteroatom N connected to the left hand side of Formula I and optionally has a second heteroatom selected from O, S, and —N(R6)—, wherein said heterocyclic group optionally has 1-2 double bonds and an optional carbonyl group and is optionally fused to a cyclic group selected from phenyl and a 5-7 membered heteroaromatic ring having 1-3 heteroatoms independently selected from O, N, and S, or is optionally connected through a spiro linkage of a carbon atom to a 5-6 membered cycloalkyl ring or to a 5-7 membered heterocyclic ring having one heteroatom selected from O, N and S(O)x, said cycloalkyl and heterocyclic ring optionally having one double bond and optionally being fused to a phenyl ring; wherein R5 including the rings optionally fused to R5 or connected to R5 through a spiro linkage is optionally substituted with 1-9 halogen atoms and is optionally substituted with 1-3 substituents independently selected from C1-C5alkyl; —OC1-C5alkyl; —NO2; —N(R9)C(═O)OCH2-phenyl; —S(O)2C1-C3alkyl; C3-C6cycloalkyl; —CO2H; —C(═O)C1-C3alkyl; —C(═O)OC1-C3alkyl; —C(═O)N(R9)2; —C1-C3alkyleneN(R9)2; —C1-C3alkyleneC(═O)N(R9)2; phenyl; —C1-C3alkylenePhenyl; a 5-10 membered heteroaromatic monocyclic or fused bicyclic group having 1-3 heteroatoms independently selected from N, O, and S; a 5-6 membered saturated or partly unsaturated heterocyclic ring having 1-3 heteroatoms independently selected from N, O, and S, optionally having a carbonyl group, optionally having one double bond, and optionally being fused to a phenyl ring; and a 5-6-membered heteroaromatic ring having 1-2 heteroatoms independently selected from N, S, and O, said heteroaromatic ring being fused to a 5-7 membered cycloalkyl or to a saturated or partly unsaturated heterocycle having 1-2 heteroatoms independently selected from N, S, and O; wherein all of said alkyl groups that are included in substituent groups on R5 are optionally substituted with 1-9 halogens, and all of said phenyl groups that are substituents on R5 or that are included in substituents on R5 are optionally substituted with 1-5 substituents independently selected from halogen, —CN, —NO2, CH3, CF3, —OCH3, and —OCF3;
R6 is selected from the group consisting of C1-C7alkyl, —C(═O)OC1-C7alkyl, —C(═O)C1-C7alkyl, —S(O)x phenyl, —S(O)x C1-C7alkyl, —C(═O)N(R9)2, —C(═O)Phenyl, —C(═O)OPhenyl, —C1-C3alkylene-C(═O)OC1-C6alkyl, —C1-C5alkylene-OC1-C5alkyl, —C(═O)C3-C7cycloalkyl, —C(═O)OC3-C7cycloalkyl, and a cyclic group selected from (a) phenyl, (b) naphthyl, (c) biphenyl, (d) C3-C8cycloalkyl, (e) a saturated or partially unsaturated monocyclic or bicyclic 5-10 membered heterocycle having 1-2 heteroatoms independently selected from N, O, and S, said heterocycle optionally having 1-2 double bonds, and (f) a monocyclic or bicyclic 5-12 membered heteroaromatic group having 1-4 heteroatoms independently selected from N, S, and O and optionally having 1-2 carbonyl groups, wherein in all instances, each alkyl, alkenyl and alkynyl group included in R6 is optionally substituted with 1-10 halogens and is also optionally substituted with 1-2 groups independently selected from phenyl, OH, biphenyl, —Ophenyl, and —OC1-C3alkylene-phenyl, wherein said phenyl substituents on the alkyl, alkenyl and alkynyl groups of R6 are optionally substituted with 1-5 substituent groups independently selected from halogen, CH3, CF3, —OCF3, —NO2 and —OCH3, and when R6 is a cyclic group selected from (a) phenyl, (b) naphthyl, (c) biphenyl, (d) C3-C8cycloalkyl, (e) a saturated or partially unsaturated monocyclic or bicyclic 5-10 membered heterocycle having 1-2 heteroatoms independently selected from N, O, and S, said heterocycle optionally having 1-2 double bonds, and (f) a cyclic or bicyclic 5-12 membered heteroaromatic group having 1-4 heteroatoms independently selected from N, S, and O and optionally having 1-2 carbonyl groups, said cyclic group R6 is optionally substituted with 1-3 groups independently selected from C1-C5alkyl, —OC1-C5alkyl, —C(═O)C1-C3alkyl, —S(O)xC1-C3alkyl, phenyl, halogen, —CN, and —NO2, said C1-C5alkyl and —OC1-C5alkyl being optionally substituted with 1-7 halogens; and
R9 is selected from the group consisting of H, C1-C5alkyl, C2-C5alkenyl, and
C2-C5alkynyl, wherein said C1-C5alkyl, C2-C5alkenyl, and C2-C5alkynyl are optionally substituted with 1-9 halogens;
With the proviso (I) that when (a) and (b) are as described below, where (a) the groups W, X, Y, and Z are each —CH═ or —(CRa)=, where the substituent groups Ra are each selected from C1, C1-C4alkyl, —OCH3, —NH2, —N(H)C(═O)OC1-C5alkyl, and —N(H)C(═O)C1-C5alkyl, wherein the alkyl groups of —N(H)C(═O)OC1-C5alkyl and —N(H)C(═O)C1-C5alkyl are optionally substituted with 1-7 halogens; and (b) A is 1,4-phenylene, which is optionally substituted, then B is not (i) —NHC(═O)CH2Ophenyl, (ii) —NHC(═O)CH2Onaphthyl, (iii) —NHC(═O)benzofuryl, (iv) —NHC(═O)benzoxazolyl, (v) —NHC(═O)CH2R5 in which R5 is a cyclic amine which is attached by a ring N atom and is selected from the group consisting of morpholinyl, piperidinyl, cbz-prolinyl and triazolyl, or (vi) —NHC(═O)CH2— connected to the N of an amine group which is selected from the group consisting of dimethylamine, t-butylglycine, and n-butylglycine, wherein phenyl, naphthyl, benzofuryl, benzoxazolyl, morpholinyl, piperidinyl, prolinyl, and triazolyl are optionally substituted;
With the further proviso (II) that when (a) and (b) are as described below, where (a) the groups W, X, Y, and Z are each —CH═ or —(CRa)=, wherein Ra is —OCH3; and (b) A is 1,4-phenylene which is optionally substituted; then B is not —N(H)C(═O)(CH2)5NH(C(═O))CF3 or —N(H)C(═O)CH(NH2)(C4alkyl);
And with the further proviso (III) that when (a) and (b) are as described below, where (a) the groups W, X, Y, and Z are each —CH═ or —(CRa)=, wherein Ra is —OCH3, halogen, C1-C4alkyl, or —NH2, and (b) A is 1,4-phenylene optionally substituted with —CH3, —OCH3, or halogen; then B is not —NHC(═O)phenyl, —NHC(═O)cyclobutyl, —NHC(═O)(CH═CH)(1,4-furyl)phenyl, —NHC(═O)(1,4-furyl)phenyl, —NHC(═O)(CH2)(CH2)(1,2,4-oxadiazolyl)phenyl, —NHC(═O)(cyclopentyl)phenyl, or NHC(═O)biphenyl, wherein phenyl in all instances is optionally substituted with 1-2 substituents independently selected from halogen, methoxy, and C1-4alkyl.

### Claim 2 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein at least one of the substituent groups Ra is —CN.

### Claim 3 (depends on 2)

The compound of claim 2 or a pharmaceutically acceptable salt thereof, wherein W, X, Y and Z are ═CH— wherein the H of each ═CH— is optionally replaced by Ra, and the H of ═CH— at the Y position is replaced by the substituent group —CN.

### Claim 4 (depends on 1)

The compound of claim 1 having Formula Ia, or a pharmaceutically acceptable salt thereof:
wherein RX and RZ are each H;
RW is selected from the group consisting of (a) C1-C5alkyl which is optionally substituted with 1-9 substituents independently selected from 1-7 halogens and 1-2 groups independently selected from —CN, —OH, —OCH3, —OCF3 and —N(R9)2, (b) C2-5 alkenyl optionally substituted with 1-5 halogens; (c) —C(═O)OC1-3alkyl optionally substituted with 1-5 halogens; (d) —C(═O)C1-C3alkyl which is optionally substituted with 1-7 halogens, (e) —C(═O)H, (f) —NO2, (g) —OC1-C3 alkyl which is optionally substituted with 1-7 halogens, (h) C3-C6cycloalkyl, (i) phenyl, (j) a 5-6 membered saturated or partly unsaturated heterocyclic ring having 1-3 heteroatoms independently selected from N, S and O, and (k) a 5-7 membered heteroaromatic ring having 1-3 heteroatoms independently selected from N, S, and O, wherein said C3-C6cycloalkyl, phenyl, 5-6 membered saturated or partly unsaturated heterocyclic ring, and 5-7 membered heteroaromatic ring are optionally substituted with 1-5 substituents independently selected from halogen, CH3, CF3, —OCH3, and —OCF3; and
RY is selected from the group consisting of Br, —OCH3, —CN, and pyridyl;
wherein proviso (I) of claim 1 is not applied to the definition of the compound of this claim.

### Claim 5 (depends on 1)

The compound of claim 1 having formula Ib, or a pharmaceutically acceptable salt thereof:
wherein RW is selected from the group consisting of (a) H, (b) C1-C5alkyl which is optionally substituted with 1-9 substituents independently selected from 1-7 halogens and 1-2 groups independently selected from —CN, —OH, —OCH3, —OCF3 and —N(R9)2, (c) C2-5 alkenyl optionally substituted with 1-5 halogens; (d) —C(═O)OC1-3alkyl optionally substituted with 1-5 halogens; (e) —C(═O)C1-C3alkyl which is optionally substituted with 1-7 halogens, (f) —C(═O)H, (g) —NO2, (h) —OC1-C3 alkyl which is optionally substituted with 1-7 halogens, (i) C3-C6cycloalkyl, (j) phenyl, (k) a 5-6 membered saturated or partly unsaturated heterocyclic ring having 1-3 heteroatoms independently selected from N, S and O, and (l) a 5-7 membered heteroaromatic ring having 1-3 heteroatoms independently selected from N, S, and O, wherein said C3-C6cycloalkyl, phenyl, 5-6 membered saturated or partly unsaturated heterocyclic ring, and 5-7 membered heteroaromatic ring are optionally substituted with 1-5 substituents independently selected from halogen, CH3, CF3, —OCH3, and —OCF3; and
R9 is independently selected from H and CH3.

### Claim 6 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein
B is selected from the group consisting of:
—(NH)(C(═O))CH2R3,
—(NH)(C(═O))CH2CH2R3,
—(NH)(C(═O))CH2—O—(CH2)3R7,
—(NH)(C(═O))OCH2R4,
—C2-C4alkyleneR3, wherein —C2-C4alkylene optionally has one difunctional group O, S, —NH—, or —N(CH3)— between two carbon atoms and is optionally substituted with 1-8 substituents independently selected from (a) 1-7 halogens, (b) 1-2 substituents independently selected from —N(R9)2, —CN, —OC1-C3 alkyl optionally substituted with 1-3 halogens, —C(═O)OH, —C(═O)H, —C(═O)OC1-C5alkyl optionally substituted with 1-7 halogens, —C(═O)C1-C5alkyl optionally substituted with 1-7 halogens, —C(═O)N(R9)2, (c) 1-2—OH groups, and (d) an oxo group on a carbon atom between two other carbon atoms of the alkylene group;
—C2-C4alkyleneR7, wherein —C2-C4alkylene optimally has one difunctional group O, S, —NH—, or —N(CH3)— between two carbon atoms and is optionally substituted with 1-8 substituents independently selected from (a) 1-7 halogens, (b) 1-2 substituents independently selected from —N(R9)2, —CN, —C(═O)OH, —C(═O)H, —C(═O)OC1-C5alkyl optionally substituted with 1-7 halogens, —C(═O)C1-C5alkyl optionally substituted with 1-7 halogens, —C(═O)N(R9)2, (c) 1-2—OH groups, and (d) an oxo group on a carbon atom between two other carbon atoms of the alkylene group;
—CH═CHCH2R3,
—CH═CHCH2R7,
—C≡CCH2R3,
—C≡CCH2R7,
—NHCH2CH2R3,
—NHCH(CF3)CH2R7,
—NHCH2C(═O)R5,
—CH(OH)CH(OH)C(═O)OC1-C4alkyl; and
Each R9 is independently selected from H and CH3.

### Claim 7 (depends on 6)

The compound of claim 6, or a pharmaceutically acceptable salt thereof, wherein:
R3 is selected from the group consisting of R4, —OR4, and —R5;
R4 is a cyclic group selected from the group consisting of:
(a) Cyclohexyl,
(b) 2-quinolyl,
(c) 1-isoquinolyl,
(d) phenyl,
(e) 2-tetrahydropyranyl,
wherein R4 is optionally substituted with 1-3 substituents independently selected from —CH3, —CF3, —OCH3, —OCF3, and halogen;
R5 is selected from the group consisting of:
wherein R10 is selected from the group consisting of —SO2CF3, —SO2CH3, and —C(═O)CH3;
R1 is selected from the group consisting of H, C1-C5alkyl, phenyl, and benzyl, wherein
C1-C5alkyl is optionally substituted with 1-3 halogens, and wherein phenyl and benzyl are optionally substituted with 1-3 groups independently selected from halogen, —CH3, —CF3, —OCH3, and —OCF3;
R12 is selected from the group consisting of H, C1-C3alkyl which is optionally substituted with 1-3 halogens, and —CH2C(═O)N(R9)2;
wherein when R5 is (a) or (d)-(g), then R5 is optionally substituted with 1-3 substituent groups independently selected from halogen, —CH3, —CF3, —OCH3, and —OCF3; and when R5 is (b) or (c), then R5 is optionally substituted with 1-2 substituents independently selected from halogen, cyclohexyl, phenyl, —C(═O)N(R9)C2-C5alkyl, —C(═O)OC1-C4alkyl, benzotriazole, pyrazolotetrahydropyridine, and —N(C2-C3alkenyl)(C(═O))Obenzyl, wherein alkyl and alkenyl are optionally substitued with 1-3 halogens, and phenyl and the phenyl of benzyl are optionally substituted with 1-3 halogens and 1 group selected from —CH3, —CF3, —OCH3, —OCF3, and —NO2;
x is an integer from 0-2;
R6 is selected from the group consisting of:
(a) phenyl,
(b) pyrimidinyl,
(c) pyrazinyl,
(d) pyridyl,
(e) naphthyl,
(f) C3-C6cycloalkyl,
(g) CH(phenyl)2,
(h) —C(═O)OC1-C5alkyl,
(i) —C(═O)C1-C5alkyl,
(j) —SO2C1-C3 alkylene-phenyl,
(k) —SO2C1-C5alkyl,
(l) —C(═O)OC3-C5alkylene-OH,
(m) —C(═O)OC3-C5alkylene-Obenzyl,
(n) —C(═O)O-phenyl,
(O) —C(═O)O-benzyl,
(p) —C(═O)N(R9)C1-C5alkyl,
(q) —C(═O)OC5-C6cycloalkyl,
(r) —CH2C(═O)OC 1-C5alkyl,
(s) C1-C3alkylene-phenyl, and
(t) C4-C6alkyl,
wherein alkyl, alkylene, and cycloalkyl groups are optionally substituted with 1-3 halogens;
phenyl, the phenyl groups of benzyl, and naphthyl are optionally substituted with 1-3 substituents independently selected from (i) halogen, (ii) C1-C3 alkyl optionally substituted with 1-3 halogens, (iii) —OCF3, (iv) —OCH3, (v) —NO2, (vii) phenyl, (viii) —CN, (ix) —C(═O)CH3, and (x) —SO2CH3; and pyridyl, pyrimidinyl and pyrazinyl are optionally substituted with 1-3 substituents independently selected from halogen, —CH3, —CF3, —OCH3, —OCF3, —NO2, —CN, and phenyl; and
R7 is selected from the group consisting of —OC3-C5alkyl, —N(R9)C(═O)OC3-C5alkyl, and —OSi(CH3)2C3-C6alkyl, wherein each alkyl group is optionally substituted with 1-3 halogens.

### Claim 8 (depends on 5)

The compound of claim 5, or a pharmaceutically acceptable salt thereof,
wherein B is selected from the group consisting of:
(a) —NHC(═O)CH2OR4
(b) —NHC(═O)CH2R3,
(c) —NHCH2CH2R3,
(d) —SCH2CH2R3,
(e) —C(═O)CH2CH2R3,
(f) —CH2CH2CH2R3, wherein the propylene chain is optionally substituted with 1-2 halogens, one —OH group, or a methylene group (═CH2),
(g) —CH2TCH2R3,
(h) —CH2C(═O)CH2R3, and
(i) —CH2CH2TR4;
T is selected from the group consisting of O, —NH—, and S;
R3 is selected from R4 and R5;
R4 is selected from the group consisting of 4-piperidinyl having an R6 substitutent on the N, cyclohexyl, and phenyl, wherein 4-piperidinyl is optionally substituted with 1-2 substitutents independently selected from F, CH3, and CF3, and phenyl and cyclohexyl are optionally substituted with 1-3 substitutents independently selected from halogen, CH3, CF3, OCH3, and OCF3;
R5 is selected from the group consisting of 1-pyrrolidinyl, 1-piperidinyl, and 1-piperazinyl, wherein the N at the 4-position of 1-piperazinyl is substituted with R6, and the pyrrolidinyl, piperidinyl, and piperazinyl groups are optionally substituted with 1-2 substituents independently selected from F, CH3, and CF3; and
R6 is selected from the group consisting of —C(═O)OC1-C5alkyl, —C(═O)C1-C3alkyl optionally substituted with 1-3F, phenyl, pyridyl, and pyrimidinyl, wherein pyridyl, pyrimidinyl, and phenyl are optionally substituted with 1-3 groups independently selected from halogen, CH3, CF3, OCH3, and OCF3, and optionally one phenyl.

### Claim 9 (depends on 8)

The compound of claim 8, wherein RW is selected from the group consisting of H, —OCH3, —OCF3, —C(═O)OCH3, C1-C3alkyl, and C2-C3alkenyl, wherein C1-C3alkyl and C2-C3alkenyl are each optionally substituted with 1-3 halogens and one —OH.

### Claim 10

A method of treating atherosclerosis or raising HDL in a patient in need of treatment comprising the administration of a therapeutically effective amount of a compound having Formula I, or a pharmaceutically acceptable salt thereof:
Wherein three of the groups W, X, Y and Z represent ═CH—, and the fourth of the groups W, X, Y, and Z represents ═CH—, ═N—, or ═N(—O)—, wherein the H of each ═CH— group optionally is replaced with a substituent group Ra, provided that at least one of the H groups is replaced with a substituent group Ra;
Q is selected from the group consisting of O, S, —CH═N—, and —N(R2)—, where the carbon of —CH═N— is attached to the 6-membered ring;
A is a difunctional cyclic group selected from 1,4-phenylene, 2,5-pyridinylene, 2,5-thienylene, 2,5-furylene, 2,5-pyrazinylene, 2,5-pyrimidinylene, and 1,4-bicyclo[2,2,2]octylene, wherein A is optionally substituted with 1-3 substituent groups Rb;
Each Ra substituent is independently selected from the group consisting of halogen, —OH, —CN, —NO2, —N(R9)2, C1-C7alkyl, OC1-C7alkyl, C2-C7alkenyl, C2-C7alkynyl, —C(═O)H, —C(═O)C1-C5alkyl, —N(R9)C(═O)C1-C5alkyl, pyridinyl, N-oxidopyridinyl, phenyl, —OPhenyl, piperidinyl, pyrimidinyl, C3-C6cycloalkyl, methyldioxolanyl, furyl, thienyl, oxazolyl, morpholinyl, isoxazolyl, —N(R9)C(═O)OC1-C5alkyl, —C(═NH)NH2, —C(═O)OC1-C5alkyl, —S(O)xC1-C7alkyl, —CH2S(O)xC1-C5alkyl, —OC(═O)C1-C5alkyl, and —OCH2C(═O)OCH2-phenyl; wherein C1-C7alkyl, C1-C5alkyl, C2-C7alkenyl, and C2-C7 alkynyl in each occurrence is optionally substituted with 1-7 halogens and is optionally substituted with one substituent selected from the group consisting of —OH, —CN, —SH, —S(O)xC1-C3alkyl, —N(R9)2, —OC1-C3alkyl, —OCF3, —OC(═O)CH3, phenyl, C3-C6cycloalkyl, —OC3-C6cycloalkyl, and —OCH2-Phenyl; wherein when Ra is phenyl or comprises a phenyl group, said phenyl group is optionally substituted with 1-3 substituents independently selected from halogen, C1-C3alkyl optionally substituted with 1-5 halogens, —OC1-C5alkyl optionally substituted with 1-5 halogens, —CN, and —C(═O)N(R9)2;
x is an integer from 0-2;
Each Rb is independently selected from the group consisting of halogen, C1-C3alkyl, C2-C3alkenyl, C2-C3alkynyl, —OCH3, and —OCF3, wherein each alkyl, alkenyl, and alkynyl substituent is optionally substituted with 1-3 halogens;
R2 is independently selected from H, C1-C5alkyl, C2-C5alkenyl, C2-C5alkynyl, —CH2C3-C6cycloalkyl, and —CH2-Phenyl, wherein each alkyl, alkenyl, and alkynyl substituent is optionally substituted with 1-7 halogens, and said phenyl and cycloalkyl groups are optionally substituted with 1-3 substituent groups independently selected from halogen, CH3, CF3, —OCH3, and —OCF3;
B is selected from the group consisting of:
—N(R9)(C(═O))DR3,
—N(R9)(C(═O))DR7,
—N(R9)(C(═O))R3,
—N(R9)(C(═O))R7,
—N(R9)(C(═O))OCH2R3,
—N(R9)D(C(═O))R7,
—N(R9)DR3,
—N(R9)D2R7,
—OD2R3,
—SD2R3,
—C(═O)CH2CH2R4,
-D2(C(═O))R7,
-D2R3,
-D2R7, and —R3;
D is a difunctional group selected from C1-C7alkylene, C2-C5alkenylene, and C2-C5alkynylene, wherein said alkylene group optionally has one difunctional group O, S, —NH— or —N(C1-C3alkyl)- between two carbon atoms of D, and said alkylene, alkenylene, and alkynylene groups are optionally substituted with 1-9 substituents independently selected from 1-7 halogens and optionally 1-2-OH groups;
D2 is a difunctional group selected from C2-C7alkylene, C2-C5alkenylene, and C2-C5alkynylene, wherein said alkylene group optionally has one difunctional group O, S, —NH— or —N(C1-C3alkyl)- between two carbon atoms of the alkylene group other than carbonyl, and said alkylene, alkenylene, and alkynylene groups are optionally substituted with 1-9 substituents independently selected from (a) 1-7 halogens, (b) 1-2 substituents independently selected from —N(R9)2, —CN, —NO2, —OC1-C3 alkyl optionally substituted with 1-3 halogens, —C(═O)OH, —C(═O)H, —C(═O)OC1-C5alkyl optionally substituted with 1-7 halogens, —C(═O)C1-C5alkyl optionally substituted with 1-7 halogens, —C(═O)N(R9)2, (c) 1-2—OH groups, and (d) an oxo group on a carbon atom between two other carbon atoms of the alkylene group;
R3 is selected from the group consisting of R4, -T-R4, and —R5;
R7 is selected from the group consisting of —OC1-C7alkyl, —CH2S(O)2C1-C7alkyl, C5-C10alkyl, —NR9C1-C7alkyl, —NR9C(═O)OC1-C7alkyl, —OC(═O)OC1-C7alkyl and —OSi(R8)3, wherein the C5-C10alkyl and C1-C7alkyl groups of R7 are optionally substituted with 1-9 halogens and are optionally substituted with one group selected from —N(R9)2, —N(R9)C(═O)OC1-C7alkyl, —N(R9)C(═O)C1-C7alkyl, and —OH, wherein the C1-C7alkyl groups of the —N(R9)C(═O)OC1-C7alkyl and —N(R9)C(═O)C1-C7alkyl substituents on R7 are optionally substituted with 1-9 halogens;
T is selected from —O—, —N(R9)—, and —S—;
Each R8 group is independently selected from C1-C5alkyl, which is optionally substituted with 1-7 halogens;
R4 is a cyclic group selected from the group consisting of
(a) C3-C8Cycloalkyl which optionally comprises 1-2 double bonds;
(b) Bicyclic C6-C12Cycloalkyl optionally comprising 1-2 double bonds;
(f) A 4-8 membered saturated or partly unsaturated heterocyclic ring having 1-2 ring members independently selected from —O— and —N(R6)—, said heterocyclic ring being connected to the left hand part of Formula I through a carbon atom of the heterocyclic ring, wherein said heterocyclic ring is optionally fused to an aromatic ring selected from phenyl and naphthyl or to a C5-C7Cycloalkyl;
(g) An aromatic ring selected from phenyl and naphthyl; and
(h) A 5-7 membered heteroaromatic ring having 1-3 heteroatoms independently selected from N, S, and O, and optionally having one —C(═O)— group as a ring member, said heteroaromatic ring being connected to the left hand part of formula I through a carbon atom of the heteroaromatic ring, wherein said heteroromatic group is optionally fused to an aromatic ring selected from phenyl and naphthyl;
Wherein said cyclic groups R4 defined in (a)-(e), including optional fused rings, are optionally substituted with 1-7 substitutents independently selected from halogen, C1-C5alkyl, —OC1-C5alkyl, phenyl, —NO2, —C(═O)C1-C5alkyl, —C(═O)OC1-C5alkyl, —C(═O)OH, and —NR9C(═O)C1-C5alkyl, wherein C1-C5alkyl and OC1-C5alkyl in all uses are optionally substituted with 1-9 halogens, and said phenyl is optionally substituted with 1-5 substituents independently selected from halogen, CH3, CF3, —OCH3, and —OCF3;
R5 is a saturated or partly unsaturated 5-8 membered monocyclic heterocyclic group or a saturated or partly unsaturated 6-10 membered bicyclic heterocyclic group, wherein said heterocyclic group has a heteroatom N connected to the left hand side of Formula I and optionally has a second heteroatom selected from O, S, and —N(R6)—, wherein said heterocyclic group optionally has 1-2 double bonds and an optional carbonyl group and is optionally fused to a cyclic group selected from phenyl and a 5-7 membered heteroaromatic ring having 1-3 heteroatoms independently selected from O, N, and S, or is optionally connected through a spiro linkage of a carbon atom to a 5-6 membered cycloalkyl ring or to a 5-7 membered heterocyclic ring having one heteroatom selected from O, N and S(O)x, said cycloalkyl and heterocyclic ring optionally having one double bond and optionally being fused to a phenyl ring; wherein R5 including the rings optionally fused to R5 or connected to R5 through a spirolinkage is optionally substituted with 1-9 halogen atoms and is optionally substituted with 1-3 substituents independently selected from C1-C5alkyl; —OC1-C5alkyl; —NO2; —N(R9)C(═O)OCH2-phenyl; —S(O)2C1-C3alkyl; C3-C6cycloalkyl; —CO2H; —C(═O)C1-C3alkyl; —C(═O)OC1-C3 alkyl; —C(═O)N(R9)2; —C1-C3alkyleneN(R9)2; —C1-C3alkyleneC(═O)N(R9)2; phenyl; —C1-C3alkylenePhenyl; a 5-10 membered heteroaromatic monocyclic or fused bicyclic group having 1-3 heteroatoms independently selected from N, O, and S; a 5-6 membered saturated or partly unsaturated heterocyclic ring having 1-3 heteroatoms independently selected from N, O, and S, optionally having a carbonyl group, optionally having one double bond, and optionally being fused to a phenyl ring; and a 5-6-membered heteroaromatic ring having 1-2 heteroatoms independently selected from N, S, and O, said heteroaromatic ring being fused to a 5-7 membered cycloalkyl or to a saturated or partly unsaturated heterocycle having 1-2 heteroatoms independently selected from N, S, and O; wherein all of said alkyl groups that are included in substituent groups on R5 are optionally substituted with 1-9 halogens, and all of said phenyl groups that are substituents on R5 or that are included in substituents on R5 are optionally substituted with 1-5 substituents independently selected from halogen, —CN, —NO2, CH3, CF3, —OCH3, and —OCF3;
R6 is selected from the group consisting of C1-C7alkyl, —C(═O)OC1-C7alkyl, —C(═O)C1-C7alkyl, —S(O)x phenyl, —S(O)x C1-C7alkyl, —C(═O)N(R9)2, —C(═O)Phenyl, —C(═O)OPhenyl, —C1-C3alkylene-C(═O)OC1-C6alkyl, —C1-C5alkylene-OC1-C5alkyl, —C(═O)C3-C7cycloalkyl, —C(═O)OC3-C7cycloalkyl, and a cyclic group selected from (a) phenyl, (b) naphthyl, (c) biphenyl, (d) C3-C8cycloalkyl, (e) a saturated or partially unsaturated monocyclic or bicyclic 5-10 membered heterocycle having 1-2 heteroatoms independently selected from N, O, and S, said heterocycle optionally having 1-2 double bonds, and (f) a monocyclic or bicyclic 5-12 membered heteroaromatic group having 1-4 heteroatoms independently selected from N, S, and O and optionally having 1-2 carbonyl groups, wherein in all instances, each alkyl, alkenyl and alkynyl group included in R6 is optionally substituted with 1-10 halogens and is also optionally substituted with 1-2 groups independently selected from phenyl, OH, biphenyl, —Ophenyl, and —OC1-C3alkylene-phenyl, wherein said phenyl substituents on the alkyl, alkenyl and alkynyl groups of R6 are optionally substituted with 1-5 substituent groups independently selected from halogen, CH3, CF3, —OCF3, —NO2 and —OCH3, and when R6 is a cyclic group selected from (a) phenyl, (b) naphthyl, (c) biphenyl, (d) C3-C8cycloalkyl, (e) a saturated or partially unsaturated monocyclic or bicyclic 5-10 membered heterocycle having 1-2 heteroatoms independently selected from N, O, and S, said heterocycle optionally having 1-2 double bonds, and (f) a cyclic or bicyclic 5-12 membered heteroaromatic group having 14 heteroatoms independently selected from N, S, and O and optionally having 1-2 carbonyl groups, said cyclic group R6 is optionally substituted with 1-3 groups independently selected from C1-C5alkyl, OC1-C5alkyl, —C(═O)C1-C3alkyl, —S(O)xC1-C3alkyl, phenyl, halogen, —CN, and —NO2, said C1-C5alkyl and —OC1-C5alkyl being optionally substituted with 1-7 halogens; and
R9 is selected from the group consisting of H, C1-C5alkyl, C2-C5alkenyl, and C2-C5alkynyl, wherein said C1-C5alkyl, C2-C5alkenyl, and C2-C5alkynyl are optionally substituted with 1-9 halogens;
with the proviso that when (a), (b), and (c) are as described below, where (a) the groups W, X, Y, and Z are each —CH═ or —(CRa)=, wherein Ra is —OCH3, halogen, C1-C4alkyl, or —NH2, (b) A is 1,4-phenylene optionally substituted with —CH3, —OCH3, or halogen, and (c) Q is S, then B is not —NHC(═O)phenyl, wherein phenyl is optionally substituted with 1-2 substituents independently selected from halogen, methoxy, and C1-4alkyl.

### Claim 11

(canceled)

### Claim 12 (depends on 3)

A method of treating atherosclerosis or raising HDL in a patient in need of treatment comprising the administration of a therapeutically effective amount of the compound of claim 3, or a pharmaceutically acceptable salt thereof.

### Claim 13

(canceled)

### Claim 14 (depends on 1)

The compound of claim 1 or a pharmaceutically acceptable salt thereof, selected from the structures below:

### Claim 15 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, selected from the structures below:
TABLE 1
EX
R1
R2
R3
39
H
Cl
40
H
Cl
41
H
Cl
42
H
Cl
43
H
Cl
44
H
Cl
45
H
Cl
46
H
Cl
47
H
Cl
48
H
Cl
49
H
Cl
50
H
Cl
51
H
Cl
52
H
Cl
53
H
Cl
54
H
Cl
55
H
Cl
56
H
Cl
57
H
Cl
58
H
Cl
59
H
Cl
60
H
Cl
61
H
Cl
62
H
Cl
63
H
CN
64
H
CN
65
H
CN
66
H
CN
67
H
CN
68
H
CN
69
H
CN
70
H
CN
71
H
CN
72
H
CN
73
H
CN
74
H
CN
75
H
CN
76
H
CN
77
H
CN
78
H
CN
79
H
CN
80
H
CN
81
H
CN
82
H
CN
83
H
CN
84
H
CN
85
H
CN
86
H
CN
87
H
CN
88
H
CN
89
H
CN
90
H
CN
91
H
CN
92
H
CN
93
H
CN
94
H
CN
95
H
CN
96
H
CN
97
H
CN
98
H
CN
99
H
CN
100
H
CN
101
H
CN
102
H
CN
103
H
CN
104
H
CN
105
H
CN
106
H
CN
107
H
CN
108
H
CN
109
H
CN
110
H
CN
111
H
CN
112
H
CN
113
H
CN
114
H
CN
115
H
CN
116
H
CN
117
H
CN
118
H
CN
119
H
CN
120
H
CN
121
H
CN
122
H
CN
123
H
CN
124
H
CN
125
H
CN
126
H
CN
127
H
CN
128
H
CN
129
H
CN
130
H
CN
131
H
CN
132
H
CN
133
H
CN
134
H
CN
135
H
CN
136
H
CN
137
H
CN
138
H
CN
139
H
CN
140
H
CN
141
H
CN
142
H
CN
143
H
CN
144
H
CN
145
H
CN
146
H
CN
147
H
CN
148
H
CN
149
H
CN
150
H
CN
151
H
CN
152
H
CN
153
H
CN
154
H
CN
155
H
CN
156
H
CN
157
CH3
CN
158
CH3
CN
159
CH3
CN
160
CH3
CN
161
CH3
CN
162
CH3
CN
163
CH3
CN
TABLE 2
EX
R1
R2
R3
165
H
CN
166
H
CN
167
H
CN
168
H
CN
169
H
CN
170
H
CN
171
H
CN
172
H
CN
173
H
CN
174
H
CN
175
H
CN
176
H
CN
177
H
CN
178
H
CN
179
H
CN
180
H
CN
181
H
CN
182
H
CN
183
H
CN
184
CH3
CN
185
CH3
CN
186
CH3
CN
187
CH3
Br
188
CH3
Br
TABLE 3
Ex
R
189
190
191
192
193
194
195
196
197
198
199
200
201
TABLE 4
Ex
R
202
203
204
TABLE 5
Ex
R4
R5
R6
R7
239
H
Ph
H
H
240
H
H
CO2CH3
H
241
H
CO2CH3
H
H
242
H
CN
H
H
243
H
Cl
CH3
H
244
CH3
Br
H
H
245
H
F
H
H
246
H
SCH3
H
H
247
H
Br
H
F
248
H
Cl
H
Cl
249
H
H
F
H
250
H
H
H
Cl
251
H
OCH3
H
H
252
H
H
NO2
H
253
H
NO2
H
H
254
CH3
H
H
H
255
H
COCH3
H
H
256
H
OH
H
H
257
H
Cl
H
NO2
258
H
Br
H
COCH3
259
H
H
H
260
H
H
H
261
H
H
H
262
H
H
CH3
263
H
H
H
264
H
H
H
265
H
H
H
266
H
H
H
267
H
H
H
268
H
H
H
269
H
H
H
270
H
Br
H
271
H
Br
H
272
H
Br
H
273
H
Br
H
274
H
Br
H
275
H
H
CN
H
276
H
CN
H
CH3
277
H
CN
H
CO2H
278
H
CN
CH3
H
279
CH3
CN
H
H
280
H
CN
H
CN
281
H
CN
H
F
282
H
CN
H
COCH3
283
H
CN
H
284
H
CN
H
285
H
CN
H
286
H
CN
H
287
H
CN
H
288
H
CN
H
TABLE 8
Ex
Structure
304
305
306
307
308
309
310
311
312
313
314
TABLE 9
Ex
R
320
321
322
323
324
325
326
327
328
329
330
331
332
TABLE 10
Ex
R1
R2
343
Br
344
Br
345
CN
346
H
347
CN
TABLE 12
Ex
R6
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
TABLE 13
Ex
R
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
TABLE 14
Ex
R6
472
473
TABLE 15
Ex
R1
R2
483
CN
484
CN
485
CN
486
Me
487
CN
488
CN
489
CN
TABLE 16
EXAMPLE
R1
R2
495
CN
496
CN
497
CN
498
CN
499
CN
TABLE 17
EXAMPLE
R
525
526
527
TABLE 18
EXAMPLE
X
R
532
CH
533
CH
534
N

### Claim 16 (depends on 1)

A pharmaceutical composition comprising a compound of claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

### Claim 17 (depends on 1)

A pharmaceutical composition comprising a compound of claim 1, or a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable carrier, and one or more active ingredients selected from the group consisting of:
(a) PPAR gamma agonists and partial agonists;
(b) biguanides;
(c) protein tyrosine phosphatase-IB (PTP-1B) inhibitors,
(d) dipeptidyl peptidase IV (DP-IV) inhibitors;
(e) insulin or insulin mimetics;
(f) sulfonylureas;
(g) α-glucosidase inhibitors;
(h) one or more compounds selected from the group consisting of (a) HMG-CoA reductase inhibitors; (b) bile acid sequestrants; (c) niacin, nicotinyl alcohol, nicotinamide, and nicotinic acid or a salt thereof; (d) PPARα agonists; (e) cholesterol absorption inhibitors; (f) acyl CoA:cholesterol acyltransferase (ACAT) inhibitors; (g) phenolic anti-oxidants, such as probucol, and (h) a microsomal triglyceride transfer protein (MTP)/ApoB secretion inhibitor;
(i) PPARα/γdual agonists;
(j) PPARδ agonists;
(k) antiobesity compounds
(l) ileal bile acid transporter inhibitors;
(m) anti-inflammatory agents;
(n) glucagon receptor antagonists;
(o) GLP-1,
(p) GIP-1, and
(q) GLP-1 analogs.
